Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT

Halvard Bönig¹, Jurjen Velthuis², Irwin Walker³, Johan Maertens⁴, Philippe Lewalle⁵, Eduardo Olavarria⁶, Dominik Selleslag⁷, Manfred Rüdiger², Menno van der Hoorn², Lisya Gerez³, Jeroen Rovers², Stephan Mielke⁸ and Denis Claude Roy⁹

¹German Red Cross Blood Center and Institute for Transfusion Medicine and Immunohematology, Johann-Wolfgang-Goethe University, Hematopoietic Cell Research Group, Frankfurt, Germany, ²Kiadis Pharma, Amsterdam-Duivendrecht, The Netherlands, ³Department of Medicine, Juravinski Hospital and Cancer Centre, Hamilton, Canada, ⁴Department of Hematology, University Hospital Gasthuisberg Leuven, Leuven, Belgium, ⁵Laboratory of Experimental Hematology, Institut Jules Bordet, ULB, Brussels, Belgium, ⁶Hammersmith Hospital, Imperial College, London, United Kingdom, ⁷AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium, ⁸Division of Hematology and Oncology, Department of Medicine II, Julius-Maximilian-University, Würzburg, Germany, ⁹Blood and Marrow Transplantation Program, Div. of Hematology-Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Quebec, Canada

Current HSCT techniques limit the use of haploidentical donor grafts as presence of donor T-cells cause severe GVHD and absence or repression of T-cells will often result in occurrence of opportunistic infections and relapse. Administering T-cells selectively depleted of alloreactivity should reduce the incidence and severity of lethal complications and GVHD and possibly reduce relapse rates. In vitro studies into the characterization of ATIR101, manufactured during an open-label, multicenter Phase II study (CR-AIR-007; NCT01794299, 23 patients with median age of 41 years (range 21-64) showed that ATIR101 consists of selectively allo-depleted donor T-cells while retaining reactivity to other unrelated antigens and stimuli (figure 1). All CD4- and CD8-positive T-cell memory subtypes (naïve, effector, central memory and effector memory) were preserved as well T-cells specific for viral peptides (figure 2) and FoxP3-positive regulatory T-cells indicating that ATIR101 retains the full mature T-cell immune repertoire but is devoid of recipient-directed alloreactivity.

ATIR101 has been administered to recipients of a CD34-selected haploidentical HSCT without the use of any immune suppression. Within 1 year follow up of the entire population, no patient developed grade III/IV acute GVHD after infusion of ATIR101. No patient died within 100 days post-HSCT and the overall survival of patients receiving ATIR101 was significantly improved compared to a historic control group, with a 1-year survival of 61% in the HSCT+ATIR101 group compared to 20% in the control group (Table 1). Only two patients receiving ATIR101 experienced a relapse within the first year, occurring at 60 and 90 days post-HSCT, respectively. Determination of GVHD-free, relapse free survival (GRFS) showed 57% GRFS in the HSCT+ATIR101 group which compares favorably to 20% GRFS in the control
group, and even to 40% GRFS in Matched Unrelated Donor (MUD) transplants collected from the same clinical centers.

This study shows that ATIR101 consists of selectively depleted alloreactive T-cells retaining the full immune repertoire; administration of a high dose of ATIR101 does not cause severe GVHD while significantly improving transplantation outcome in the absence of immune suppression.

**Figure 1. Selective depletion of recipient-reactivity in ATIR101**

ATIR 101 and original donor cells were stimulated with either irradiated donor cells (autologous), irradiated recipient cells, irradiated 3rd party cells or anti CD3/28. ATIR101 is selectively depleted of recipient-reactivity only (P<0.05, n= 23)

**Figure 2. Anti-viral T-cells in donor and ATIR101**

ATIR101 and original donor cells were stained with PE-labeled HLA-A2 multimers. Pathogen-specific T-cells are preserved in ATIR101.

**Table 1**

<table>
<thead>
<tr>
<th>Kaplan-Meier Estimates of:</th>
<th>6 months after HSCT</th>
<th>12 months after HSCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival</td>
<td>83% [HAPLO 63%]</td>
<td>61% [HAPLO 20%]</td>
</tr>
<tr>
<td>Relapse-Related Mortality</td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td>GRFS</td>
<td>78% [HAPLO 57%]</td>
<td>57% [HAPLO 20%]</td>
</tr>
</tbody>
</table>